We analyzed the correlation between FIGNL1 expression and DFS using the Kaplan–Meier method (Figure 4). The median DFS of 58 NSCLC patients was 28.90 months (18.05∼39.75 months). The median DFS of NSCLC patients with FIGNL1 positive expression was 22.00 months (9.67∼34.34 months). The median DFS of NSCLC patients with FIGNL1 negative expression was 42.00 months (25.21∼58.79 months). The DFS of NSCLC patients with high expression of FIGNL1 was significantly shorter (P = 0.032)....FIGNL1 is associated with poor prognosis in NSCLC, and cisplatin resistance may be involved.